Use of a Commercial Assay for Detecting the 60 kDa Chlamydial Heat Shock Protein in a Range of Patient Groups.

The article examines the use of a commercial assay for detecting the 60 kDa Chlamydial heat shock protein in a range of female patient groups presenting with varying histories of Chlamydial trachomatis infection, sequelae and uninfected controls. The consistent level of cHSP60 antibody found across all female patients regardless of pathology may limit the ability of the assay to differentiate between the disease states. The study also showed that there was no higher prevalence among the group with tubal damage/pelvic inflammatory disease.